MedTrace Logo

Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma

NCT05693012 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 398

Last updated 2023-01-20

No results posted yet for this study

Summary

It is an observational, case-control study aimed at early-detection of multiple myeloma and constructing a prognostic model of multiple myeloma. The study will enroll approximately 398 participants including patients with multiple myeloma, patients with benign hematologic disorders and healthy participants.

Conditions

Interventions

DIAGNOSTIC_TEST

cfDNA methylation assessment

An exploratory study to establish the early detection and prognosis models of multiple myeloma patients in China based on plasma cf DNA methylation assessment

Sponsors & Collaborators

  • Guangzhou Burning Rock Dx Co., Ltd.

    collaborator INDUSTRY

  • Qiu Lugui

    lead OTHER

Principal Investigators

  • Lugui Qiu, MD, Ph.D · Chinese Academy of Medical Sciences & Peking Union Medical College

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05693012 on ClinicalTrials.gov